Alembic Pharma gets one procedural observation for Vadodara facility
Vadodara: Alembic Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded an inspection with one procedural observation at the Company's Bioequivalence Facility located at Vadodara.
The inspection was conducted from 3rd March, 2025 to 7th March, 2025.
This was a scheduled inspection. The USFDA issued a Form 483 with one procedural observation.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
"The Company will provide comprehensive response to USFDA for the observations within the stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times," Alembic stated in a filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.